EA200700431A1 - CONJUGATES OF CHEMICALLY MODIFIED HUMAN GROWTH HORMONE - Google Patents

CONJUGATES OF CHEMICALLY MODIFIED HUMAN GROWTH HORMONE

Info

Publication number
EA200700431A1
EA200700431A1 EA200700431A EA200700431A EA200700431A1 EA 200700431 A1 EA200700431 A1 EA 200700431A1 EA 200700431 A EA200700431 A EA 200700431A EA 200700431 A EA200700431 A EA 200700431A EA 200700431 A1 EA200700431 A1 EA 200700431A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chemically modified
growth hormone
human growth
conjugates
modified human
Prior art date
Application number
EA200700431A
Other languages
Russian (ru)
Inventor
Рори Ф. Финн
Уэй Лэйо
Нед Р. Сиджел
Original Assignee
Фармация Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Корпорейшн filed Critical Фармация Корпорейшн
Publication of EA200700431A1 publication Critical patent/EA200700431A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Abstract

Согласно настоящему изобретению предложен химически модифицированный гормон роста человека (hGH), полученный путем связывания водорастворимого полимера с белком. Химически модифицированный белок по настоящему изобретению может иметь намного более продолжительную активность hGH, чем активность немодифицированного hGH, что дает возможность снизить дозу и создать благоприятные условия режима введения.According to the present invention, a chemically modified human growth hormone (hGH), obtained by binding a water-soluble polymer to a protein, is proposed. The chemically modified protein of the present invention can have a much longer activity of hGH than the activity of unmodified hGH, which makes it possible to reduce the dose and create favorable conditions for the administration regimen.

EA200700431A 2001-11-20 2002-11-20 CONJUGATES OF CHEMICALLY MODIFIED HUMAN GROWTH HORMONE EA200700431A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
EA200700431A1 true EA200700431A1 (en) 2008-02-28

Family

ID=23295870

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200400565A EA008505B1 (en) 2001-11-20 2002-11-20 Chemically modified human growth hormone conjugates
EA200700431A EA200700431A1 (en) 2001-11-20 2002-11-20 CONJUGATES OF CHEMICALLY MODIFIED HUMAN GROWTH HORMONE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200400565A EA008505B1 (en) 2001-11-20 2002-11-20 Chemically modified human growth hormone conjugates

Country Status (25)

Country Link
EP (1) EP1453859A2 (en)
JP (2) JP2005525302A (en)
KR (2) KR20050044858A (en)
CN (1) CN1608079A (en)
AP (1) AP2004003050A0 (en)
AU (1) AU2002356990A1 (en)
BR (1) BR0214451A (en)
CA (1) CA2467731A1 (en)
CO (1) CO5580794A2 (en)
EA (2) EA008505B1 (en)
EC (1) ECSP045114A (en)
GE (1) GEP20063860B (en)
HR (1) HRP20040448A2 (en)
HU (1) HUP0500997A2 (en)
IL (1) IL162031A0 (en)
IS (1) IS7268A (en)
MA (1) MA27544A1 (en)
MX (1) MXPA04004809A (en)
NO (1) NO20042182L (en)
OA (1) OA13063A (en)
PL (1) PL374354A1 (en)
RS (1) RS53104A (en)
TN (1) TNSN04090A1 (en)
WO (1) WO2003044056A2 (en)
ZA (1) ZA200403907B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
KR100964411B1 (en) * 2002-01-18 2010-06-15 바이오겐 아이덱 엠에이 인코포레이티드 Polyalkylene glycol with moiety for conjugating biologically active compound
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US7157546B2 (en) 2002-09-09 2007-01-02 Nektar Therapeutics Al, Corporation Water-soluble polymer alkanals
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
ES2349743T3 (en) * 2003-10-10 2011-01-11 Novo Nordisk A/S DERIVATIVES OF IL-21.
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
RU2385879C2 (en) * 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Method of conjugating peptides, mediated by transglutaminase
AP2007003919A0 (en) * 2004-08-31 2007-02-28 Pharmacia & Upjohn Co Llc Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof
SG161210A1 (en) * 2004-12-22 2010-05-27 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
KR20070090023A (en) * 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 Modified human growth hormone
DK2399893T3 (en) * 2004-12-22 2018-10-08 Ambrx Inc COMPOSITIONS CONTAINING, INVOLVING PROCEDURES, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES
WO2006084888A2 (en) 2005-02-10 2006-08-17 Novo Nordisk A/S C-terminally pegylated growth hormones
EP1877439B1 (en) 2005-04-18 2011-02-09 Novo Nordisk A/S Il-21 variants
AU2006286486A1 (en) 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
RS51998B (en) * 2005-11-08 2012-04-30 Ambrx Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
EP1968635B1 (en) 2005-12-14 2014-09-17 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
AU2007271150A1 (en) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
CN101108895B (en) * 2006-07-19 2011-10-26 北京键凯科技有限公司 Polyglycol ethanal derivant and combo of medicament and the same
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
CL2008002399A1 (en) 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
ES2453946T3 (en) 2008-04-03 2014-04-09 Biosteed Gene Expression Tech. Co., Ltd. Growth hormone modified with double stranded polyethylene glycol, method of preparation and application of this
KR101104574B1 (en) * 2008-05-14 2012-01-11 성균관대학교산학협력단 Human growth hormone derivative linked with polyethyleneglycol, method for the preparation thereof and pharmaceutical composition comprising the same
JP5639585B2 (en) * 2008-07-31 2014-12-10 ファーマエッセンティア コーポレイション Peptide-polymer conjugate
MX2011000847A (en) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy.
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
JP5766118B2 (en) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション Polymeric alpha-hydroxyaldehyde and ketone reagents and conjugation methods
US8513192B2 (en) 2009-01-22 2013-08-20 Novo Nordisk A/S Stable growth hormone compounds resistant to proteolytic degradation
JP6086528B2 (en) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Growth hormone with long-term in vivo efficacy
SG181648A1 (en) 2009-12-15 2012-07-30 Ascendis Pharma As Dry growth hormone composition transiently linked to a polymer carrier
RU2012134974A (en) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг STABILIZED GROWTH HORMONE COMPOUND
TWI508737B (en) 2010-01-22 2015-11-21 諾佛 儂迪克股份有限公司 Growth hormones with prolonged in-vivo efficacy
NZ603399A (en) * 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (en) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Polyethyleneglycol covalent conjugate with human growth hormone
ES2841123T3 (en) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Growth hormone compound formulation
EP4282485A3 (en) 2014-11-06 2024-01-17 PharmaEssentia Corporation Dosage regimen for pegylated interferon
IL254389B2 (en) * 2015-03-11 2023-03-01 Nektar Therapeutics Conjugates of an il-7 moiety and an polymer
SG11201802180TA (en) 2015-09-18 2018-04-27 Univ Miyazaki Long-acting adrenomedullin derivative
CN114539384A (en) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 Pegylated long-acting growth hormone, and preparation method and medical application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DK0458064T3 (en) * 1990-05-04 1998-04-27 American Cyanamid Co Stabilization of somatotropins by modifying cysteine residues
CA2101918A1 (en) * 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69635026T2 (en) * 1995-09-21 2006-05-24 Genentech Inc., San Francisco VARIANTS OF HUMAN GROWTH HORMONE
DE69838552T2 (en) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ES2204509T3 (en) * 1999-01-29 2004-05-01 F. Hoffmann-La Roche Ag CONJUGATES OF GCSF.
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
OA13063A (en) 2006-11-10
KR20050044858A (en) 2005-05-13
PL374354A1 (en) 2005-10-17
MXPA04004809A (en) 2004-08-11
EP1453859A2 (en) 2004-09-08
HUP0500997A2 (en) 2007-11-28
TNSN04090A1 (en) 2006-06-01
JP2005525302A (en) 2005-08-25
BR0214451A (en) 2006-05-30
CN1608079A (en) 2005-04-20
JP2006321808A (en) 2006-11-30
HRP20040448A2 (en) 2006-02-28
CO5580794A2 (en) 2005-11-30
AU2002356990A1 (en) 2003-06-10
IL162031A0 (en) 2005-11-20
WO2003044056A2 (en) 2003-05-30
ECSP045114A (en) 2004-07-23
RS53104A (en) 2006-10-27
IS7268A (en) 2004-05-17
EA200400565A1 (en) 2005-06-30
ZA200403907B (en) 2007-12-27
CA2467731A1 (en) 2003-05-30
AP2004003050A0 (en) 2004-06-30
MA27544A1 (en) 2005-10-03
NO20042182L (en) 2004-08-11
KR20070072924A (en) 2007-07-06
WO2003044056A3 (en) 2003-08-21
EA008505B1 (en) 2007-06-29
GEP20063860B (en) 2006-06-26

Similar Documents

Publication Publication Date Title
EA200700431A1 (en) CONJUGATES OF CHEMICALLY MODIFIED HUMAN GROWTH HORMONE
DK1715887T3 (en) N-terminal Monopegylated Human Growth Hormone Conjugates, Methods for their Preparation and Use
HUP0400313A2 (en) A novel engineered superantigen for human therapy
WO2005000359A3 (en) Chemically-modified human growth hormone conjugates
EP2360176A3 (en) Hybrid and tandem expression of neisserial derived proteins
MY169272A (en) Her2 antibody composition
BR0208183A (en) Peptide modified by wt1
ATE376559T1 (en) METHODS OF PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE
CY1107628T1 (en) HUMAN CTLA-4 ANTIBODIES AND USES
EP2107071A3 (en) Anti-EpCAM immunoglobulins
SI1734995T1 (en) Monoclonal antibodies to hepatocyte growth factor
ATE447858T1 (en) PHARMACEUTICAL COMPOSITION FOR MUSCLE ANABOLISM
CY1108377T1 (en) USE OF 1-FENYLO-3-DIMETHYLAMINO-PROPANIUM COMPOUNDS FOR TREATMENT OF URINE CONTENT
WO2005013918A3 (en) Compositions, methods and kits relating to poxvirus subunit vaccines
BR0213821A (en) Polymer / peptide conjugates Thymosin alfa 1
DK1583529T3 (en) Amino acid phenoxy ethers, preparation and use thereof
HUP0402334A2 (en) Modified human growth hormone
EA200400392A1 (en) BINDING KASPAZU-8 PROTEIN, ITS OBTAINING AND APPLICATION
WO2003000179A3 (en) Chemically-modified progenipoietin conjugates
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
FR2821359B1 (en) HETEROCARPINE, A PROTEIN FIXING HUMAN GHRH
WO2000058438A3 (en) Conformationally constrained peptides
RU2350351C2 (en) Compositions and medicinal forms on basis of gastrinum, application and reception methods
WO2004050703A8 (en) Splice variant of the human pituitary growth hormone